Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nurix Therapeutics (NRIX) has granted inducement awards to 13 new employees on May 13, 2025, as part of their 2024 Equity Inducement Plan. The awards include stock options to purchase 87,950 shares of common stock at $9.73 per share and restricted stock unit awards (RSUs) for 60,050 shares.
The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will also vest over 4 years, with 25% vesting after one year and the remainder vesting quarterly. Both awards are subject to continued employment.
Nurix Therapeutics (NRIX) ha assegnato premi di incentivo a 13 nuovi dipendenti il 13 maggio 2025, nell'ambito del loro Piano di Incentivi Azionari 2024. I premi includono opzioni su azioni per l'acquisto di 87.950 azioni ordinarie a 9,73 dollari per azione e unità azionarie vincolate (RSU) per 60.050 azioni.
Le opzioni azionarie matureranno in 4 anni, con il 25% che matura dopo un anno e il resto che matura mensilmente. Anche le RSU matureranno in 4 anni, con il 25% che matura dopo un anno e il resto che matura trimestralmente. Entrambi i premi sono vincolati al mantenimento del rapporto di lavoro.
Nurix Therapeutics (NRIX) otorgó premios de incentivo a 13 nuevos empleados el 13 de mayo de 2025, como parte de su Plan de Incentivos de Capital 2024. Los premios incluyen opciones sobre acciones para comprar 87,950 acciones ordinarias a 9.73 dólares por acción y unidades de acciones restringidas (RSU) por 60,050 acciones.
Las opciones sobre acciones se consolidarán durante 4 años, con un 25% consolidado después de un año y el resto consolidándose mensualmente. Las RSU también se consolidarán durante 4 años, con un 25% consolidado después de un año y el resto consolidándose trimestralmente. Ambos premios están sujetos a la continuidad del empleo.
Nurix Therapeutics (NRIX)는 2025년 5월 13일, 2024년 주식 유인 계획의 일환으로 13명의 신입 직원에게 유인 보상을 부여했습니다. 보상에는 주당 9.73달러에 보통주 87,950주를 매수할 수 있는 스톡 옵션과 60,050주의 제한 주식 단위(RSU)가 포함됩니다.
스톡 옵션은 4년에 걸쳐 권리가 부여되며, 1년 후 25%가 권리 취득되고 나머지는 매월 권리 취득됩니다. RSU 또한 4년에 걸쳐 권리가 부여되며, 1년 후 25%가 권리 취득되고 나머지는 분기별로 권리 취득됩니다. 두 보상 모두 계속 고용 조건이 적용됩니다.
Nurix Therapeutics (NRIX) a accordé des primes d'incitation à 13 nouveaux employés le 13 mai 2025, dans le cadre de leur Plan d'Incitation en Actions 2024. Les primes comprennent des options d'achat d'actions pour 87 950 actions ordinaires au prix de 9,73 $ par action et des unités d'actions restreintes (RSU) pour 60 050 actions.
Les options d'achat d'actions seront acquises sur une période de 4 ans, avec 25 % acquis après un an et le reste acquis mensuellement. Les RSU seront également acquises sur 4 ans, avec 25 % acquis après un an et le reste acquis trimestriellement. Les deux primes sont conditionnées à la poursuite de l'emploi.
Nurix Therapeutics (NRIX) hat am 13. Mai 2025 Anreizprämien an 13 neue Mitarbeiter im Rahmen ihres Aktienanreizplans 2024 vergeben. Die Prämien umfassen Aktienoptionen zum Kauf von 87.950 Stammaktien zu je 9,73 US-Dollar sowie Restricted Stock Units (RSUs) für 60.050 Aktien.
Die Aktienoptionen werden über 4 Jahre erworben, wobei 25 % nach einem Jahr und der Rest monatlich vesten. Die RSUs vesten ebenfalls über 4 Jahre, mit 25 % nach einem Jahr und dem Rest vierteljährlich. Beide Prämien sind an eine fortlaufende Beschäftigung gebunden.
- None.
- None.
SAN FRANCISCO, May 16, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on May 13, 2025, the company granted inducement awards to thirteen new employees. The grants were made pursuant to Nurix’s 2024 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted stock options to purchase an aggregate of 87,950 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 60,050 shares of Nurix common stock.
One fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee’s date of hire and one forty-eighth of the total number of shares underlying the stock options will vest each month thereafter until the stock option is fully vested on the fourth anniversary of the employee’s date of hire, subject to the employee’s continued service with Nurix on each such vesting date. The stock options have a term of ten years and an exercise price of
One fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the RSU vesting start date, which is April 30, 2025, subject to the employee’s continued service with Nurix on the vesting date. Thereafter, one sixteenth of the total number of shares subject to the RSUs shall vest quarterly, until the RSU award is fully vested on the fourth anniversary of the vesting start date, subject to the employee’s continued service with Nurix on each such vesting date.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What inducement awards did Nurix Therapeutics (NRIX) grant to new employees in May 2025?
What is the vesting schedule for Nurix's (NRIX) May 2025 stock option grants?
How do the RSUs vest in Nurix's (NRIX) May 2025 inducement grants?
What is the exercise price for Nurix's (NRIX) May 2025 inducement stock options?
